JP6903559B2 - 血圧降下用組成物 - Google Patents
血圧降下用組成物 Download PDFInfo
- Publication number
- JP6903559B2 JP6903559B2 JP2017234358A JP2017234358A JP6903559B2 JP 6903559 B2 JP6903559 B2 JP 6903559B2 JP 2017234358 A JP2017234358 A JP 2017234358A JP 2017234358 A JP2017234358 A JP 2017234358A JP 6903559 B2 JP6903559 B2 JP 6903559B2
- Authority
- JP
- Japan
- Prior art keywords
- blood pressure
- composition
- administration
- peptide
- ace
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 61
- 230000036772 blood pressure Effects 0.000 title claims description 38
- 235000013305 food Nutrition 0.000 claims description 31
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 26
- 230000005764 inhibitory process Effects 0.000 claims description 24
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 11
- JUWJEAPUNARGCF-DCAQKATOSA-N Leu-Arg-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JUWJEAPUNARGCF-DCAQKATOSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 29
- 238000000034 method Methods 0.000 description 21
- 230000004531 blood pressure lowering effect Effects 0.000 description 16
- 230000035488 systolic blood pressure Effects 0.000 description 15
- 206010020772 Hypertension Diseases 0.000 description 14
- 241000282412 Homo Species 0.000 description 10
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 9
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 9
- 239000005541 ACE inhibitor Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 102000005862 Angiotensin II Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 3
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 238000009530 blood pressure measurement Methods 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- -1 p-toluenesulfonyl group Chemical group 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QBNXAGZYLSRPJK-JEDNCBNOSA-N N(gamma)-nitro-L-arginine methyl ester hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O QBNXAGZYLSRPJK-JEDNCBNOSA-N 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 108090001109 Thermolysin Proteins 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000008960 ketchup Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
項0.
Leu−Arg−Alaからなるトリペプチドを含む、血圧降下用組成物。
項1.
ACE阻害による血圧降下不奏功、又はACE阻害禁忌の対象のための、
Leu−Arg−Alaからなるトリペプチドを含む、血圧降下用組成物。
項2.
ACE阻害による血圧降下不奏功、又はACE阻害禁忌の対象のための、
Leu−Arg−Alaからなるトリペプチドを含む、血管における一酸化窒素産生促進用組成物。
項3.
経口組成物である、項0、1又は2に記載の組成物。
項4.
食品組成物又は医薬品組成物である、項0及び1〜3のいずれかに記載の組成物。
項5.
対象がヒトである、項0及び1〜4のいずれかに記載の組成物。
製造例1:Fmoc法によるトリペプチドの合成
Fmoc法によりLeu−Arg−Alaからなるトリペプチド(LRAペプチド)を固相合成した。得られたLRAトリペプチドをHPLCにより精製した後、プロテインシーケンサーにより配列を解析した結果、Leu−Arg−Alaからなるトリペプチドであることが確認された。
製造例2:Boc法によるトリペプチドの合成
Boc法によるLRAペプチドの合成を株式会社ペプチド研究所に依頼した。なお、納品されたLRAペプチドは、RP−HPLC、質量分析及びアミノ酸分析により、Leu−Arg−Alaからなるトリペプチドであることが確認されたものであった。
実施例1:血圧降下作用の検討
実験動物として、雄性の高血圧自然発症ラット (SHR/Izm、12週齢;清水実験材料社)を用いた。飼料は固形SP飼料(船橋農場)、飲用水は水道水を使用し、試験中も含め自由摂食・自由飲水とした。ラットは、3週間(13〜15週齢)血圧測定への馴化期間を設けた後、本試験に使用した。なお、ラットは、LRAペプチド投与群及び対照群の2群に群分けした(各群:N=5)。
LRAペプチドが奏する血圧降下効果が、一酸化窒素(NO)を介して得られているものかを調べるため、一酸化窒素合成酵素(NOS)阻害剤であるL−NAMEを投与した場合にも血圧降下効果が得られるのかを検討した。なお、同人堂社から購入したL−NAME塩酸塩を検討に用いた。
Claims (5)
- ACE阻害による血圧降下不奏功、又はACE阻害禁忌の対象のための、
Leu−Arg−Alaからなるトリペプチドを含む、血圧降下用組成物。 - ACE阻害による血圧降下不奏功、又はACE阻害禁忌の対象のための、
Leu−Arg−Alaからなるトリペプチドを含む、血管における一酸化窒素産生促進用組成物。 - 経口組成物である、請求項1又は2に記載の組成物。
- 食品組成物又は医薬品組成物である、請求項1〜3のいずれかに記載の組成物。
- 対象がヒトである、請求項1〜4のいずれかに記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017234358A JP6903559B2 (ja) | 2017-12-06 | 2017-12-06 | 血圧降下用組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017234358A JP6903559B2 (ja) | 2017-12-06 | 2017-12-06 | 血圧降下用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019099526A JP2019099526A (ja) | 2019-06-24 |
JP6903559B2 true JP6903559B2 (ja) | 2021-07-14 |
Family
ID=66975856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017234358A Active JP6903559B2 (ja) | 2017-12-06 | 2017-12-06 | 血圧降下用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6903559B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7114245B2 (ja) * | 2017-12-06 | 2022-08-08 | サンスター株式会社 | ペプチド含有組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006108211A1 (en) * | 2005-02-25 | 2006-10-19 | The Murdoch Childrens Research Institute | Fragments of von willebrand factor a-related protein |
-
2017
- 2017-12-06 JP JP2017234358A patent/JP6903559B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019099526A (ja) | 2019-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6987757B2 (ja) | 新規トリペプチド | |
JP5832049B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
JP6189994B2 (ja) | ジペプチジルペプチダーゼ−iv阻害用飲食品組成物 | |
WO2005012334A1 (ja) | 生体内非分解性ペプチド、アンジオテンシン変換酵素阻害剤、医薬及び機能性食品 | |
JP2007523940A (ja) | 抗高血圧ペプチド | |
JP6344796B2 (ja) | 高齢者用アルツハイマー型認知症改善剤 | |
JP2015084694A (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
JP6903559B2 (ja) | 血圧降下用組成物 | |
JP5976004B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
JP4628958B2 (ja) | アンジオテンシン変換酵素阻害ペプチド | |
JP5877560B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
JP7334311B2 (ja) | ペプチド含有組成物 | |
JP7114245B2 (ja) | ペプチド含有組成物 | |
JP7068942B2 (ja) | トリペプチド含有組成物 | |
WO2021239642A1 (en) | Peptides capable of inducing anorexic hormones, compositions and uses thereof | |
JP6345630B2 (ja) | 新規ペプチド及びその用途 | |
JP2022007697A (ja) | 脳機能改善用組成物 | |
JP2019108364A (ja) | 栄養組成物 | |
JP6119969B2 (ja) | 血圧降下用アミノ酸含有組成物 | |
JP2022007698A (ja) | 脳機能改善用組成物 | |
JP2020002018A (ja) | ペンタペプチド及び該ペプチド含有組成物 | |
JP2021107358A (ja) | グレリン受容体の活性化剤 | |
JP2018154640A (ja) | 脳機能障害改善用経口組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201007 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210430 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210525 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210623 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6903559 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |